Granted Patent
B2
US 12,637,452 · App. 17/292,663 · Granted May 26, 2026
Crystalline forms of a substituted imidazopyridine compound and use thereof as P2X3 modulator
Inventors:
Denis Garceau (Laval, CA); Robert M. Wenslow, Jr. (Laval, CA); Kemal Payza (Laval, CA); Nathalie Chauret (Laval, CA)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Described herein are crystalline forms of a P2X3 modulator, namely (S)-methyl-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate or a solvate thereof, and use thereof for treating pain, urinary tract disorder, cough, pruritus and endometriosis.
Claims (4)
1 . A crystalline form of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate, or solvate thereof, wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern with characteristic peaks at about 6.9° 2-Theta, 11.3° 2-Theta, 11.5° 2-Theta, 12.8° 2-Theta, 17.8° 2-Theta, 20.7° 2-Theta, 21.6° 2-Theta, and 22.6° 2-Theta.
2 . The crystalline form of claim 1 , wherein the crystalline form is obtained from acetonitrile, acetone, tert-butyl methyl ether, water, methanol, ethanol, isopropanol, propanol, butanol, diethyleneglycol, ethyl acetate, isopropyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylsulfoxide, dimethylformamide, methyl ethyl ketone, methyl isobutyl ketone, butyl acetate, hexane, heptane, dichloromethane, chloroform, 1,2-dichloroethane, dimethoxyethane, toluene, anisole, or combinations thereof.
3 . A pharmaceutical composition comprising the crystalline form of claim 1 , and at least one inactive ingredient selected from pharmaceutically acceptable carriers, diluents, and excipients.
4 . The crystalline form of claim 1 , wherein the crystalline form is obtained from acetonitrile, acetone, tert-butyl methyl ether, water, methanol, ethanol, isopropanol, propanol, butanol, diethyleneglycol, isopropyl acetate, tetrahydrofuran, 2-methyltetrahydrofuran, dimethylsulfoxide, dimethylformamide, methyl ethyl ketone, methyl isobutyl ketone, butyl acetate, hexane, heptane, dichloromethane, chloroform, 1,2-dichloroethane, dimethoxyethane, toluene, anisole, or combinations thereof.
Assignments (6)
CHANGE OF ADDRESS
Recorded Apr 16, 2025
From: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED
Reel/Frame 071351/0192 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 19, 2024
From: 14245563 CANADA INC.
To: ID BIOMEDICAL CORPORATION OF QUEBEC
Reel/Frame 066353/0331 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 19, 2024
From: ID BIOMEDICAL CORPORATION OF QUEBEC
To: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED
Reel/Frame 066353/0356 →
MERGER
Recorded Aug 9, 2023
From: BELLUS HEALTH COUGH INC.
To: BELLUS HEALTH INC.
Reel/Frame 064531/0830 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 9, 2023
From: BELLUS HEALTH INC.
To: 14245563 CANADA INC.
Reel/Frame 065117/0909 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 5, 2021
From: CHAURET, NATHALIE; GARCEAU, DENIS; PAYZA, KEMAL; WENSLOW, ROBERT M., JR.
To: BELLUS HEALTH COUGH INC.
Reel/Frame 057708/0209 →
Continuity (2)
Provisional Application
62760307
· Nov 13, 2018
References Cited (126)
US 6673908B1
· Stanton, Jr.
· 2004
[cited by examiner]
US 7550495B2
· Page et al.
· 2009
[cited by applicant]
US 8530467B2
· Cantin et al.
· 2013
[cited by applicant]
US 9598409B2
· Buon
· 2017
[cited by examiner]
US 9814725B2
· Buon et al.
· 2017
[cited by applicant]
US 9937815B2
· Smidebrant et al.
· 2018
[cited by applicant]
US 20030124028A1
· Carlson
· 2003
[cited by examiner]
US 20060264490A1
· Page et al.
· 2006
[cited by applicant]
US 20150290181A1
· Lee et al.
· 2015
[cited by applicant]
US 20150361078A1
· Buon et al.
· 2015
[cited by applicant]
US 20170143730A1
· Buon et al.
· 2017
[cited by applicant]
US 20170326141A1
· Trower
· 2017
[cited by applicant]
US 20180015099A1
· Buon et al.
· 2018
[cited by applicant]
US 20190300957A1
· Gonsky et al.
· 2019
[cited by applicant]
US 20200390779A1
· Buon et al.
· 2020
[cited by applicant]
US 20210228588A1
· Buon et al.
· 2021
[cited by applicant]
US 20210322432A1
· Garceau et al.
· 2021
[cited by applicant]
US 20210346391A1
· Matzouranis et al.
· 2021
[cited by applicant]
CA 921395A
· 1973
[cited by applicant]
CA 2655780A1
· 2007
[cited by applicant]
CA 2777746A1
· 2011
[cited by applicant]
CA 2898665A1
· 2014
[cited by applicant]
CA 2921395A1
· 2015
[cited by applicant]
CA 2998742A1
· 2017
[cited by applicant]
CN 102741245A
· 2012
[cited by applicant]
EP 0533266A1
· 1993
[cited by applicant]
EP 2501697A1
· 2012
[cited by applicant]
JP 2004002826A
· 2004
[cited by applicant]
RU 2294935C2
· 2007
[cited by applicant]
WO WO9722596A1
· 1997
[cited by applicant]
WO WO9730035A1
· 1997
[cited by applicant]
WO WO9732856A1
· 1997
[cited by applicant]
WO WO9813354A1
· 1998
[cited by applicant]
WO WO9902166A1
· 1999
[cited by applicant]
WO WO0040529A1
· 2000
[cited by applicant]
WO WO0041669A2
· 2000
[cited by applicant]
WO WO0047212A1
· 2000
[cited by applicant]
WO WO0192224A1
· 2001
[cited by applicant]
WO WO0194341A1
· 2001
[cited by applicant]
WO WO0204434A1
· 2002
[cited by applicant]
WO WO0208213A1
· 2002
[cited by applicant]
WO WO02085309A2
· 2002
[cited by applicant]
WO WO2006119504A2
· 2006
[cited by applicant]
WO WO2007147478A1
· 2007
[cited by applicant]
WO WO2008136756A1
· 2008
[cited by applicant]
WO WO2010033168A2
· 2010
[cited by applicant]
WO WO2011062550A1
· 2011
[cited by applicant]
WO WO2014117274A1
· 2014
[cited by applicant]
WO WO2016091776A1
· 2016
[cited by applicant]
WO WO2017160569A1
· 2017
[cited by applicant]
WO WO2018064135A1
· 2018
[cited by applicant]
WO WO2019064079A2
· 2019
[cited by applicant]
WO WO2020099923A1
· 2020
[cited by applicant]
WO WO2020112890A1
· 2020
[cited by applicant]
WO WO2020135771A1
· 2020
[cited by applicant]
WO WO2020174283A1
· 2020
[cited by applicant]
WO WO2021161105A1
· 2021
[cited by applicant]
WO WO2021161109A1
· 2021
[cited by applicant]
Hurst et al., Analytica Chimica Acta, 337 (1997), 233-52 (Year: 1997).
[cited by examiner]
Campbell Roberts et al., J. Pharm. Biomed. Anal., 28 (2002) 1149-59 (Year: 2002).
[cited by examiner]
Tiwari et al., J. Pharm. Biomed. Anal., 43 (2007) 865-72 (Year: 2007).
[cited by examiner]
Strachan, C.J., Rades, T., Gordon, K.C. and Rantanen, J. (2007), Raman spectroscopy for quantitative analysis of pharmaceutical solids. Journal of Pharmacy and Pharmacology, 59: 179-192. https://doi.org/10.1211/jpp.59.2…
[cited by examiner]
F. Sáez-Orellana et al. / Pharmacological Research 101 (2015) 109-115 (Year: 2015).
[cited by examiner]
Gardner et al. (Computers and Chemical Engineering 28 (2004) 943-953) (Year: 2004).
[cited by examiner]
Abdulqawi et al. P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lance 385(9974):1198-1205 (2015).
[cited by applicant]
Baviskar et al.: N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase llα and induce apoptosis in G1/S phase. J Med Chem. 54(14):5013-5030 (2011).
[cited by applicant]
Berge et al.: Pharmaceutical Salts. Journal of Pharmaceutical Science. 66:1-19 (1997).
[cited by applicant]
Bernstein: Crystal Structure Prediction and Polymorphism. ACA Transactions. 39:14-23 (2004).
[cited by applicant]
Braga et al.: Making crystals from crystals: a green route to crystal engineering and polymorphism. Chem. Commun. 3635-3645 (2005).
[cited by applicant]
Byrn et al.: Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations. Pharmaceutical Research. vol. 12, No. 7, 945-954 (1995).
[cited by applicant]
Cantin et al., “Discovery of P2X3 Selective Antagonists for the Treatment of Chronic Pain.” Bioorganic & Medicinal Chemistry Letters, 22(7):2565-2571, 2012.
[cited by applicant]
Chauret et al., BLU-5937, A potent and selective P2X3 antagonist, for the treatment of chronic itch: evidence from pre-clinical studies. Journal of Investigative Dermatology 139(9S):S232 (2019).
[cited by applicant]
Chen et al. “A P2X purinoceptor expressed by a subset of sensory neurons”, Nature, 377(6548):428-431, 1995.
[cited by applicant]
Chernyak and Gevorgyan, “General and Efficient Copper-Catalyzed Three-Component Coupling Reaction towards Imidazoheterocycles. One-Pot Synthesis of Alpidem and Zolpidem,” Angewandte Chemie International Edition, 49(15):…
[cited by applicant]
Cockayne et al. “Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X 3-deficient mice.” Nature, 407(6807):1011-1015, 2000.
[cited by applicant]
Deady, Ring nitrogen oxidation of amino substituted nitrogen heterocycles with m-Chloroperbenzoic acid. Syn. Comm., 7(8):509-514, 1977.
[cited by applicant]
Ding et al.: P2X3 receptor involvement in endometriosis pain via ERK signaling pathway; PLOS One 12(9) pp. 1-17 (2017).
[cited by applicant]
Fabbretti, ATP-gated P2X3 receptors are specialised sensors of the extracellular environment. Advances in Experimental Medicine and Biology 1051:7-16 (2017).
[cited by applicant]
Ford et al., The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Frontiers in Cellular Neuroscience 7:267 [1-10] (2013).
[cited by applicant]
Ford, In pursuit of P2X3 antagonists: novel therapeutics for chronic pain and afferent sensitization. Purinergic Signalling 8(Suppl 1):3-26 (2012).
[cited by applicant]
Garceau et al., BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Pulmonary Pharmacology and Therapeutics 56:56-62 (2019).
[cited by applicant]
Garcia-Guzman et al., “Molecular characterization and pharmacological properties of the human P2X3 purinoceptor”, Mol. Brain Res., 47(1-2):59-66, 1997.
[cited by applicant]
Han, et al., A subpopulation of nociceptors specifically linked to itch. Nat Neurosci. Feb. 2013; 16(2):174-82. doi: 10.1038/nn.3289. Epub Dec. 23, 2012.
[cited by applicant]
Jarvis et al.: A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. PNAS. 99(26:17179-17184 (2002).
[cited by applicant]
Jones et al.: Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement. MRS Bulletin. 31:875-879 (2006).
[cited by applicant]
Joule et al., Heterocyclic Chemistry, Third edition, Chapter 11, “The diazines: pyridazine, pyrimidine and pyrazine: reactions and synthesis.” London: Cheapman and Hall, p. 189-225, 1995.
[cited by applicant]
Kamei et al., Involvement of ionotropic purinergic receptors in the histamine-induced enhancement of the cough reflex sensitivity in guinea pigs. Eur J Pharmacol 547:160-164, 2006.
[cited by applicant]
Kamei et al., Involvement of P2X receptor subtypes in ATP-induced enhancement of the cough reflex sensitivity. Eur J Pharmacol 528:158-161, 2005.
[cited by applicant]
Kwong et al., P2X2 receptors differentiate placodal vs. neural crest C-fiber phenotypes innervating guinea pig lungs and esophagus. AJP Lung Cell Mol Physiol., 295:L858-L865, 2008.
[cited by applicant]
Lewis et al. “Coexpression of P2X2 and P2X3 receptor subunits can account for ATP-gated currents in sensory neurons”, Nature, 377(6548):432-435, 1995.
[cited by applicant]
Lombardo et al., Discovery of N-(2-Chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl kinase inhibitor with potent antitumor …
[cited by applicant]
Mackenzie et al., Drug Discovery Today: Disease Models, 1(3):297-302, 2004.
[cited by applicant]
Marucci et al., Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. Expert Opinion on Therapeutic Patents 29(12):943-963 (2019).
[cited by applicant]
North, The P2X3 subunit: a molecular target in pain therapeutics. Current Opinion in Investigational Drugs 4(7):833-840 (2003).
[cited by applicant]
PCT/CA2014/050062 International Preliminary Report on Patentability dated Aug. 4, 2015.
[cited by applicant]
PCT/CA2014/050062 International Search Report and Written Opinion dated Apr. 29, 2014.
[cited by applicant]
PCT/IB2018/001513 International Preliminary Report on Patentability dated Apr. 2, 2020.
[cited by applicant]
PCT/IB2018/001513 International Search Report and Written Opinion dated Apr. 2, 2019.
[cited by applicant]
PCT/IB2019/001122 International Preliminary Report on Patentability dated Apr. 22, 2021.
[cited by applicant]
PCT/IB2019/001122 International Search Report and Written Opinion dated Feb. 10, 2020.
[cited by applicant]
PCT/IB2019/001199 International Preliminary Report on Patentability dated May 27, 2021.
[cited by applicant]
PCT/IB2019/001199 International Search Report and Written Opinion dated Mar. 3, 2020.
[cited by applicant]
PCT/IB2020/000160 International Preliminary Report on Patentability dated Sep. 2, 2021.
[cited by applicant]
PCT/IB2020/000160 International Search Report and Written Opinion dated Jun. 15, 2020.
[cited by applicant]
PCT/IB2021/000091 International Search Report and Written Opinion dated May 25, 2021.
[cited by applicant]
PCT/IB2021/000130 International Search Report and Written Opinion dated Jun. 14, 2021.
[cited by applicant]
Price: The computational prediction of pharmaceutical crystal structures and polymorphism. Advanced Drug Delivery Reviews. 56:301-319 (2004).
[cited by applicant]
Shiratori-Hayashi et al., Role of P2X3 receptors in scratching behavior in mouse models. Journal of Allergy and Clinical Immunology 143(3):1252-1254 (2019).
[cited by applicant]
Silverman et al. Chapter 8: Prodrugs and drug delivery systems. In: The Organic Chemistry of Drug Design and Drug Action. San Diego: Academic Press, Inc. p. 352-401 (1992).
[cited by applicant]
Trower et al., Neurokinin-1 receptor antagonist orvepitant is an effective inhibitor of itch-associated response in a Mongolian gerbil model of scratching behaviour. Experimental Dermatology 23(11):858-860 (2014).
[cited by applicant]
Ugo Basile 2012 Catalog; https://analab.gr/wp-content/uploads/Ugo-Basile-Catalogue-2012.pdf XP055483468 (2012).
[cited by applicant]
U.S. Appl. No. 16/375,773 Office Action dated Jul. 9, 2019.
[cited by applicant]
Vilotti et al.: B-Type Natriuretic Peptide-Induced Delayed Modulation of TRPV1 and P2X3 Receptors of Mouse Trigeminal Sensory Neurons. PLoS One. 8(11):e81138 (2013).
[cited by applicant]
Yuan et al.: Effect of A-3177491 delivered by glycolipid-like polymer micelles on endometriosis pain. Int. J. Nanomedicine. 12:8171-8183 (2017).
[cited by applicant]
Zhong et al., Bladder and cutaneous sensory neurons of the rat express different functional P2X receptors. Neuroscience, 120(3):667-675, 2003.
[cited by applicant]
Balbach, S., et al., “Pharmaceutical evaluation of early development candidates The 100 mg approach”, International Journal of Pharmaceutics, 2004, vol. 275, p. 1-12.
[cited by applicant]
Braga et al., “Crystal Polymorphism and Multiple Crystal Forms”, 2009, pp. 25-50.
[cited by applicant]
Caira M R, “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry, Springer, Berlin, DE, (Jan. 1, 1998), vol. 198, ISSN 0340-1022, pp. 163-208.
[cited by applicant]
Hilfker, Rolf, “Relevance of Solid-State Properties for Pharmaceutical Products”, 2006, pp. 1-19.
[cited by applicant]
Hirayama, “Handbook for organic compounds crystal preparation”, 2008, pp. 17-23, 37-40, 45-51, 57-65 (document to present well-known arts). Machine translation attached.
[cited by applicant]
Singhal, D. et al., “Drug polymorphism and dosage form design: a practical perspective”, Advanced Drug Delivery Reviews, 2004, vol. 56, p. 335-347.
[cited by applicant]
Polymorphism in pharmaceutical solids; edited by Brittain HG, Marcel Dekker Inc., Grant DJW (chapter 1) pp. 1-55, Guillory JK (chapter 5) pp. 183-226, ISBN: 0-8247-0237-9, Dec. 31, 1999.
[cited by applicant]
Yang L., et al., “Drug Crystalline Forms,” People's Medical Publishing House, 2009, vol. 2, pp. 1-12, 28 Pages.
[cited by applicant]